New contrast dye aims to sharpen MRI images of body lesions

NCT ID NCT07275723

Completed Diagnosis Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests a new contrast agent called HRS-9231 for MRI scans of body parts (excluding the brain and spine). The goal is to see if it makes abnormal blood vessels or lesions show up as clearly as a standard contrast agent. About 309 adults who already need a contrast MRI are participating. Each person gets both the new and standard agent at different times to compare image quality and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOR CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF ABNORMAL VASCULAR LESIONS IN BODY REGIONS EXCLUDING THE CENTRAL NERVOUS SYSTEM (CNS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vascular malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOR CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF ABNORMAL VASCULAR LESIONS IN BODY REGIONS EXCLUDING THE CENTRAL NERVOUS SYSTEM (CNS)

Contacts and locations

Show contact details

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China